Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry.

[reaction: see text] Botulinum neurotoxins (BoNTs), etiological agents of the deadly food poisoning disease botulism, are the most toxic proteins currently known. By using in situ lead identification chemistry, we have uncovered the first class of inhibitors that displays nanomolar potency. From a 15 microM lead compound, structure-activity relationship studies were performed granting the most potent BoNT/A inhibitor reported to date that displays an inhibition constant of 300 nM.

[1]  R. Stevens,et al.  Crystal structure of botulinum neurotoxin type A and implications for toxicity , 1998, Nature Structural Biology.

[2]  N. Ede,et al.  Synthesis of hydroxamic acids using SynPhase™ crowns: Development of the hydroxylamine trityl linker , 1999, Letters in Peptide Science.

[3]  Apurba K Bhattacharjee,et al.  The medicinal chemistry of botulinum, ricin and anthrax toxins. , 2005, Current medicinal chemistry.

[4]  L. Simpson,et al.  Identification of the major steps in botulinum toxin action. , 2004, Annual review of pharmacology and toxicology.

[5]  K. Mori,et al.  Synthesis of trichostatin a, a potent differentiation inducer of friend leukemic cells, and its antipode , 1988 .

[6]  Christopher J Burns,et al.  Nanomolar Inhibitors for Two Distinct Biological Target Families from a Single Synthetic Sequence: A Next Step in Combinatorial Library Design? , 1998, Angewandte Chemie.

[7]  S. M. Dankwardt.  SOLID PHASE SYNTHESIS OF HYDROXAMIC ACIDS , 1998 .

[8]  Leonard A. Smith,et al.  Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  H. V. Van Wart,et al.  Solid-phase synthesis of di- and tripeptidic hydroxamic acids as inhibitors of procollagen C-proteinase. , 2000, Bioorganic & Medicinal Chemistry Letters.

[10]  A. Koskinen,et al.  A NOVEL LINKAGE FOR THE SOLID-PHASE SYNTHESIS OF HYDROXAMIC ACIDS , 1997 .

[11]  J. Marks,et al.  Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. , 2002, Vaccine.

[12]  Philip K. Russell,et al.  Botulinum toxin as a biological weapon: medical and public health management. , 2001, JAMA.

[13]  M. Whittaker,et al.  A method for the synthesis of hydroxamic acids on solid phase , 1996 .

[14]  Rick Gussio,et al.  Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. , 2003, Biochemical and biophysical research communications.

[15]  D. Zaharevitz,et al.  Conformational sampling of the botulinum neurotoxin serotype A light chain: implications for inhibitor binding. , 2005, Bioorganic & medicinal chemistry.

[16]  W. Chan,et al.  N-Fmoc-aminooxy-2-chlorotrityl polystyrene resin: A facile solid-phase methodology for the synthesis of hydroxamic acids☆ , 1997 .

[17]  Y. Pang,et al.  Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A. , 2006, Bioorganic & medicinal chemistry.

[18]  B. Barlaam,et al.  Solid-phase synthesis of hydroxamic acid based TNF-α convertase inhibitors☆ , 1999 .